Cargando…
Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
Autores principales: | Cadegiani, Flavio A., Wambier, Carlos G., Goren, Andy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399048/ https://www.ncbi.nlm.nih.gov/pubmed/32850920 http://dx.doi.org/10.3389/fmed.2020.00453 |
Ejemplares similares
-
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS)
por: Cadegiani, Flavio A., et al.
Publicado: (2020) -
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020) -
Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
por: Cadegiani, Flavio A, et al.
Publicado: (2021) -
Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS)
por: Revercomb, Lucy, et al.
Publicado: (2021) -
Use of Spironolactone in SARS-CoV-2 ARDS Patients
por: Dumanlı, Güleren Yartaş, et al.
Publicado: (2020)